Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Due to economic reasons, thalidomide is still widely used as a first line drug for Multiple
Myeloma patients in China. However,the efficacy of CTd is still lower than the therapeutic
regimens with new drugs. Clarithromycin may have partly efficacy in association with steroids
and thalidomide for Multiple Myeloma patients. This multicenter, randomized, phase 3 clinical
trial is proposed to explore whether clarithromycin could potentiate responsiveness of CTd
(Cyclophosphamide, Thalidomide and Dexamethasone) regimen in Newly Diagnosed Multiple Myeloma
patients. The trial will also evaluate the side effects caused by the combination of these
drugs.